New drug combo aims to shrink tumors before colon cancer surgery
NCT ID NCT07156682
Summary
This study is testing whether adding a new two-drug immunotherapy (QL1706) to standard chemotherapy before surgery can help shrink tumors in people with a common type of stage III colon cancer. About 21 patients will receive the drug combination for about 3 months, followed by surgery. The main goal is to see if the treatment completely eliminates the tumor by the time of surgery, which could improve long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu hospital of Shandong University
Jinan, Shandong, 250012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.